Harbinger Capital Disposes Shares of Harbinger Group Inc (HRG)

Phil Falcone’s Harbinger Capital Partners has sold around 2.72 million shares of Harbinger Group Inc (NYSE:HRG), a recent SEC filing showed. The fund reported that the transaction happened in 18th of February, 2014. Harbinger Capital Partners sold Harbinger Group Inc (NYSE:HRG) shares at $6.5 apiece. Harbinger Capital Partners owns 73.8 million shares of Harbinger Group Inc (NYSE:HRG) following the sale.


The transaction price of $6.5 per share represents an option price of shares since the closing price of the Harbinger Group Inc (NYSE:HRG) shares was $11.46 per share on the date of the deal.  

While Harbinger is the largest shareholder of Harbinger Group, Leon Cooperman’s Omega Advisors owns 6.5 million shares of the company. The fund’s position represents the second largest chunk of shares. JHL Capital Group, managed by James H. Litinsky, owns 1.48 million shares, with a reported value of $17.5 million. Harbinger Group Inc (NYSE:HRG) had no insider purchases since 2009. However, the company insiders sold 29.5 million shares in 2013 at an average price of $9.46 per share.

Harbinger Capital Partners was founded in 2001 by the billionaire investor Philip Falcone. The fund invests heavily in consumer goods and conglomerates. The fund’s top holdings include Harbinger Group Inc (NYSE:HRG), Spectrum Brands Holdings, Inc. (NYSE:SPB), and North American Energy Partners Inc. (NYSE:NOA).

Harbinger Group Inc (NYSE:HRG) is a holding company and its subsidiaries provide consumer goods and financial services. The company offers batteries, herbicides, insecticides, pet supplies, electric shavers, grooming products, small appliances, personal care products, and financial services. The company was founded in 1954 and is headquartered in New York, New York.

Disclosure: none

Recommended Reading:

Richard Blum’s Latest 13F Shows Strong Focus on Services

Broadfin Capital Initiates Stake in Eleven Biotherapeutics (EBIO) Following Its IPO

Hedge Fund News: Thomas Steyer, David Einhorn & Carl Icahn

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!